Brokerages Set Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) PT at $299.48

Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) have received a consensus rating of “Moderate Buy” from the twenty-five research firms that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and nineteen have issued a buy rating on the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $304.26.

A number of equities analysts recently commented on ALNY shares. Needham & Company LLC restated a “buy” rating and issued a $320.00 price objective on shares of Alnylam Pharmaceuticals in a report on Wednesday. Sanford C. Bernstein cut their price target on shares of Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating on the stock in a report on Tuesday, January 7th. Wolfe Research lowered shares of Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a research note on Tuesday, November 12th. Canaccord Genuity Group increased their target price on shares of Alnylam Pharmaceuticals from $384.00 to $385.00 and gave the stock a “buy” rating in a research report on Tuesday, February 18th. Finally, StockNews.com lowered Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, January 9th.

Alnylam Pharmaceuticals Trading Down 0.5 %

Shares of NASDAQ:ALNY opened at $243.86 on Monday. The firm has a fifty day moving average of $254.33 and a two-hundred day moving average of $262.59. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27. Alnylam Pharmaceuticals has a 12-month low of $141.98 and a 12-month high of $304.39. The firm has a market capitalization of $31.57 billion, a P/E ratio of -112.38 and a beta of 0.35.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). On average, equities analysts expect that Alnylam Pharmaceuticals will post -1.7 EPS for the current fiscal year.

Insider Activity

In other news, CEO Yvonne Greenstreet sold 1,213 shares of the firm’s stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $255.17, for a total transaction of $309,521.21. Following the completion of the transaction, the chief executive officer now directly owns 81,526 shares of the company’s stock, valued at approximately $20,802,989.42. This trade represents a 1.47 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CMO Pushkal Garg sold 52,592 shares of Alnylam Pharmaceuticals stock in a transaction dated Monday, January 27th. The shares were sold at an average price of $285.00, for a total transaction of $14,988,720.00. Following the sale, the chief marketing officer now owns 11,989 shares in the company, valued at approximately $3,416,865. This trade represents a 81.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 72,986 shares of company stock worth $20,397,849. Company insiders own 1.50% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Huntington National Bank grew its stake in shares of Alnylam Pharmaceuticals by 91.8% in the 3rd quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 45 shares during the period. Hollencrest Capital Management acquired a new stake in Alnylam Pharmaceuticals in the 3rd quarter valued at $29,000. Larson Financial Group LLC grew its position in Alnylam Pharmaceuticals by 187.2% in the fourth quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 73 shares during the period. R Squared Ltd bought a new stake in Alnylam Pharmaceuticals in the fourth quarter valued at $33,000. Finally, Colonial Trust Co SC acquired a new position in Alnylam Pharmaceuticals during the fourth quarter worth $35,000. Institutional investors own 92.97% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.